Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma

Hematol Oncol Clin North Am. 1997 Oct;11(5):975-86. doi: 10.1016/s0889-8588(05)70474-3.

Abstract

Drug resistance remains a significant obstacle to improving therapeutic outcome following treatment for malignant lymphoma. Eliminating P-glycoprotein as one mechanism of drug resistance may select for alternative, non-P-glycoprotein mechanisms of drug resistance. Understanding these alternative forms of drug resistance is imperative in order to improve therapy for NHL.

Publication types

  • Review

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • ATP-Binding Cassette Transporters / metabolism*
  • Antineoplastic Agents / pharmacokinetics
  • Apoptosis
  • DNA Repair
  • DNA Topoisomerases, Type II / metabolism
  • Drug Resistance, Multiple
  • Drug Resistance, Neoplasm*
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / metabolism*
  • Neoplasm Proteins / metabolism*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • ATP-Binding Cassette Transporters
  • Antineoplastic Agents
  • Neoplasm Proteins
  • DNA Topoisomerases, Type II